Loading company…
ID 405089522 · FY 2020–2024 · 5 years
ძირითად საქმიანობას წარმოადგენს ფარმაცევტული და პარაფარმაციის პროდუქტების იმპორტ-ექსპორტი და საბითუმო რეალიზაცია.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 435 | 662 | 1,081 | 1,966 | 3,389 | +67.1% |
| Net Cash used in Investing Activities | 0 | -409 | -284 | -86 | -3 | nmf |
| Free Cash Flow (OCF − Capex proxy) | 435 | 253 | 797 | 1,880 | 3,386 | +67.0% |
| Net Cash from Financing Activities | -383 | -309 | -745 | -1,810 | -1,691 | +45.0% |
| Net Change in Cash (before FX) | 52 | -56 | 52 | 69 | 1,695 | +138.8% |
| Net Change in Cash (incl. FX) | 52 | -56 | 52 | 69 | 1,695 | +138.8% |
| Cash at Beginning of Year | 4 | 57 | 1 | 53 | 122 | +129.4% |
| Cash at End of Year | 57 | 1 | 53 | 122 | 1,817 | +138.1% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Ownership & directors from companyinfo.ge (public corporate registry).